Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Geftinat Gefitinib Tablets IP:
Introducing Geftinat, a targeted therapy containing Gefitinib, specifically formulated for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations.
Uses of Geftinat Gefitinib Tablets IP:
Geftinat Tablets are used for:
Treating non-small cell lung cancer (NSCLC) with EGFR mutations
Inhibiting cancer cell growth and proliferation
Providing a targeted treatment option for advanced or metastatic NSCLC
Benefits of Geftinat Gefitinib Tablets IP:
Targeted action against EGFR-mutant cancer cells
Effective in reducing tumor size and progression
Improves overall survival rates in NSCLC patients
Convenient oral administration for patient compliance
Mechanism of Action of Geftinat Gefitinib Tablets IP:
Gefitinib works by selectively inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the growth and proliferation of cancer cells. By blocking this pathway, Gefitinib effectively reduces cancer cell survival and proliferation, leading to tumor shrinkage and slower disease progression.